Literature DB >> 14504619

Treatment of spasticity in a spinal cord-injured patient with intrathecal morphine due to intrathecal baclofen tolerance--a case report and review of literature.

B M Soni1, R M Mani, T Oo, S Vaidyanathan.   

Abstract

STUDY
DESIGN: Case report.
OBJECTIVE: To report treatment of spasticity in a spinal cord-injured person with intrathecal morphine after the person developed tolerance to intrathecal baclofen.
METHOD: Spasticity in a 36-year-old man with T6 complete paraplegia was treated with increasing doses of intrathecal baclofen. When he developed tolerance to intrathecal baclofen, he was given continuous infusion of morphine intrathecally.
SETTING: Regional Spinal Injuries Centre, UK.
RESULTS: Spasticity was adequately controlled by intrathecal morphine.
CONCLUSION: In spinal cord-injured patients with severe spasticity, who become tolerant to intrathecal baclofen, treatment with intrathecal morphine may be useful.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504619     DOI: 10.1038/sj.sc.3101471

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  9 in total

1.  Suppression of stretch reflex activity after spinal or systemic treatment with AMPA receptor antagonist NGX424 in rats with developed baclofen tolerance.

Authors:  Masakatsu Oshiro; Michael P Hefferan; Osamu Kakinohana; Nadezda Lukacova; Kazuhiro Sugahara; Tony L Yaksh; Martin Marsala
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Chronic baclofen desensitizes GABA(B)-mediated G-protein activation and stimulates phosphorylation of kinases in mesocorticolimbic rat brain.

Authors:  Bradley M T Keegan; Thomas J R Beveridge; Jeffrey J Pezor; Ruoyu Xiao; Tammy Sexton; Steven R Childers; Allyn C Howlett
Journal:  Neuropharmacology       Date:  2015-02-25       Impact factor: 5.250

Review 3.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 4.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  [Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

Authors:  M Neuburger; M Schley; M Schmelz; G Schuepfer; C Konrad
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

6.  Differential development of tolerance to the functional and behavioral effects of repeated baclofen treatment in rats.

Authors:  T J R Beveridge; H R Smith; L J Porrino
Journal:  Pharmacol Biochem Behav       Date:  2013-03-13       Impact factor: 3.533

7.  Systemic naloxone infusion may trigger spasticity in patients with spinal cord injury: case series.

Authors:  Nancy L Brackett; Emad Ibrahim; Andrei Krassioukov; Charles M Lynne
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

8.  Combinational spinal GAD65 gene delivery and systemic GABA-mimetic treatment for modulation of spasticity.

Authors:  Osamu Kakinohana; Michael P Hefferan; Atsushi Miyanohara; Tetsuya Nejime; Silvia Marsala; Stefan Juhas; Jana Juhasova; Jan Motlik; Karolina Kucharova; Jan Strnadel; Oleksandr Platoshyn; Peter Lazar; Jan Galik; Laurent Vinay; Martin Marsala
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

9.  Spinal Myoclonus Responding to Continuous Intrathecal Morphine Pump.

Authors:  Jung-Eun Ahn; Dallah Yoo; Ki-Young Jung; Jong-Min Kim; Beomseok Jeon; Myung Chong Lee
Journal:  J Mov Disord       Date:  2017-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.